8-K: HOOKIPA Pharma to Delist from Nasdaq, Pursue Dissolution Following Gilead Asset Sale

HOOKIPA Pharma Inc. announced its intention to voluntarily delist its common stock from the Nasdaq Capital Market and deregister its securities, leading to the company's dissolution and liquidation after an asset sale to Gilead Sciences, Inc.

Summary

• HOOKIPA Pharma Inc. (HOOK) has formally notified Nasdaq of its intention to voluntarily delist its common stock and deregister its securities under Section 12(b) and 12(g) of the Exchange Act, and suspend reporting obligations under Section 15(d).
• The decision follows the company's entry into an Asset Purchase Agreement with Gilead Sciences, Inc. on May 21, 2025, for the sale of assets primarily related to its HB-400 (hepatitis B) and HB-500 (HIV) clinical development programs.
• A special meeting of stockholders is scheduled for July 29, 2025, at 10:00 a.m. Eastern Time, to seek approval for the Asset Sale and the dissolution and liquidation of HOOKIPA.
• The company anticipates filing a Form 25 with the SEC on or about July 29, 2025, with the delisting and Section 12(b) deregistration expected to become effective on or about August 8, 2025.
• Following the delisting, HOOKIPA intends to file a Form 15 to deregister under Section 12(g) and suspend reporting, with full deregistration expected 90 days after the Form 15 filing.
• The company cited the economic burden of continued compliance with reporting requirements post-asset sale and prior to dissolution as a key reason for the decision, noting it would reduce assets available for stockholder distribution.
• Upon stockholder approval and closing of the Asset Sale, HOOKIPA intends to file a Certificate of Dissolution with the Delaware Secretary of State, commencing the winding up and liquidation process.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative as the company is ceasing public operations, delisting, and moving towards dissolution and liquidation. While an asset sale is occurring, it is in the context of winding down the company, not as a growth strategy.

Positives

• The Asset Purchase Agreement with Gilead Sciences, Inc. secures value for HOOKIPA's HB-400 and HB-500 clinical programs, which will contribute to the assets available for ultimate distribution to stockholders during the liquidation process.

Negatives

• Voluntary delisting of common stock from the Nasdaq Capital Market will result in a loss of public trading liquidity for shareholders.
• Deregistration of securities under the Exchange Act will cease the company's public reporting obligations, reducing transparency.
• The company's ultimate dissolution and liquidation signify the cessation of its operations as a going concern.
• There is no guarantee that a broker will make a market in the common stock or that trading will continue on an over-the-counter market following delisting.

Risks

• Uncertainty of stockholder approval for both the Asset Sale and the dissolution and liquidation of HOOKIPA.
• Risks related to the timing and ability of HOOKIPA to successfully close the Asset Sale.
• Uncertainty regarding the timing and effectiveness of HOOKIPA's delisting and deregistration of its common stock.
• Potential insufficiency of existing cash to fund operations through the winding-up process.
• The possibility that no active trading market will exist for HOOKIPA's common stock following its delisting from Nasdaq.

Future Outlook

HOOKIPA Pharma anticipates completing an asset sale to Gilead Sciences, Inc., followed by a voluntary delisting from Nasdaq, deregistration of its common stock, and ultimately the dissolution and liquidation of the company, pending stockholder approval. The company expects to cease its public reporting obligations.

Management Comments

• The decision to voluntarily delist and deregister was made after considering that continued compliance with reporting requirements would be economically burdensome following the Asset Sale and announced intent to dissolve and liquidate, which would reduce assets available for ultimate distribution to stockholders.

Industry Context

This announcement reflects a specific strategic decision by HOOKIPA Pharma to wind down its public operations and liquidate, following the sale of key clinical assets to a larger pharmaceutical company, Gilead Sciences. While asset sales and strategic realignments are common in the biopharmaceutical industry, a full dissolution and liquidation of a publicly traded company is less frequent and typically indicates a shift away from independent public operations.

Stakeholder Impact

• Shareholders: Will lose the ability to trade shares on Nasdaq, face reduced liquidity, and will ultimately receive a distribution of remaining assets upon liquidation, the value of which is uncertain.
• Employees: Implied impact on employment due to the company's dissolution and liquidation, though not explicitly stated.
• Customers/Partners: The HB-400 and HB-500 programs will be transferred to Gilead Sciences, Inc., potentially impacting existing collaborations or future product availability under HOOKIPA's name.

Next Steps

• Hold a special meeting of stockholders on July 29, 2025, to seek approval for the Asset Sale and the dissolution and liquidation.
• File a Form 25 with the SEC on or about July 29, 2025, to effect voluntary withdrawal of listing and deregistration under Section 12(b).
• File a Certificate of Dissolution with the Delaware Secretary of State as soon as practicable following the closing of the Asset Sale and completion of the transfer plan, if stockholders approve.
• File a Form 15 with the SEC following the effectiveness of the Form 25 to deregister under Section 12(g) and suspend reporting obligations under Section 15(d).
• Commence the winding up and liquidation of HOOKIPA upon filing of the Certificate of Dissolution.

Key Dates

Recommendation

Keywords

HOOKIPA Pharma, Delisting, Deregistration, Dissolution, Liquidation, Asset Sale, Gilead Sciences, Biopharmaceutical, Nasdaq, SEC Filing, HB-400, HB-500, Hepatitis B, HIV, Clinical-stage